Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of LM-24C5 in Combination With Other Anti-tumor Treatment in Subjects With CEACAM5-positive Advanced Solid Tumors

NCT07387081 is registered in ClinicalTrials.gov with LaNova Medicines Limited as lead sponsor.

NCT NCT07387081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07387081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of LM-24C5 in Combination With Other Anti-tumor Treatment in Subjects With CEACAM5-positive Advanced Solid Tumors
Lead sponsor
LaNova Medicines Limited
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2025
Completion date
October 25, 2028
Enrollment
130 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor cancer